Letibotulinumtoxin A is a Protein owned by Hugel, and is involved in 19 clinical trials, of which 16 were completed, and 3 are ongoing.

Botulinum toxin acts through proteolysis of intracellular target proteins (SNAP 25) which results in blocking of neurotransmitter release and results in temporary flaccid paralysis of asociated muscles and treats blepharospasm. It blocks neuromuscular transmission by binding to acceptor sites on motor nerve terminals, entering the nerve terminals, and inhibiting the release of acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a pre-synaptic protein integral to the successful docking and release of acetylcholine from vesicles situated within nerve endings.

The revenue for Letibotulinumtoxin A is expected to reach a total of $16.3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Letibotulinumtoxin A NPV Report.

Letibotulinumtoxin A is currently owned by Hugel. Sihuan Pharmaceutical Holdings Group is the other company associated in development or marketing of Letibotulinumtoxin A.

Letibotulinumtoxin A Overview

Clostridium Botulinum toxin type A (Botulax / Letybo) is a neurotoxic protein produced from fermentation of Hall strain Clostridium botulinum type A. It is formulated as lyophilised powder for solution for intramuscular route of administration. It is indicated for the treatment of benign essential eye lid spasm (blepharospasm).

Sihuan Pharmaceutical Holdings Group Overview

Sihuan Pharmaceutical Holdings Group (Sihuan Pharmaceutical) is a pharmaceutical company that develops, manufactures, and markets prescription drugs. The company offers products in the therapeutic areas of Cardio-Cerebral Vascular, Digestive System, Anti-Infective, Metabolism, Respiratory, Neurology, and Others. It offers products under the brand names Tenedid, Tenaxin, Xiangtong, Aogan, Aohuan, Aoying, Aomeina, Ren’ao, Ashenqnuooqi, Aosaixin, and Huineng among others. The company sells its products through its distribution to network hospitals and medical institutions in Zhejiang, Guangdong, and Henan. Sihuan Pharmaceutical is headquartered in Beijing City, Beijing, China.

The company reported revenues of (Renminbi) CNY3,291.3 million for the fiscal year ended December 2021 (FY2021), an increase of 33.6% over FY2020. In FY2021, the company’s operating margin was 23.2%, compared to an operating margin of 31.9% in FY2020. In FY2021, the company recorded a net margin of 12.7%, compared to a net margin of 19.2% in FY2020.

Quick View – Letibotulinumtoxin A

Report Segments
  • Innovator (NME)
Drug Name
  • Letibotulinumtoxin A
Administration Pathway
  • Intramuscular
Therapeutic Areas
  • Ophthalmology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.